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Sir,
In their publication ‘Mathematical models of targeted cancer
therapy’ Abbott and Michor (2006) emphasise the role of
theoretical modelling for the understanding of cancer initiation,
progression and treatment. Herein, they draw a number of general
conclusions from a model of BCR-ABL1-positive chronic myeloid
leukaemia (CML) under imatinib treatment that has recently been
published by Michor et al (2005). This model relies on the
existence of four subsequent compartments, through which
haematopoietic cell differentiation proceeds. Chronic myeloid
leukaemia development is initiated by the mutation of a single
stem cell, and the expansion of the malignant (i.e. BCR-ABL1-
positive) clone is assumed to be completely independent of the
normal cells. Imatinib treatment, which is known to specifically
affect BCR-ABL1-positive cells, is assumed to act on progenitor
and differentiated cells only. In contrast, malignant stem cells are
not affected and continue to expand exponentially. Abbott and
Michor (2006) show that these assumptions are consistent with
clinical data on BCR-ABL1 transcript levels during the first year of
imatinib treatment as well as after treatment cessation.
Recent data on the long-term development of CML under
imatinib monotherapy show a continuing decrease of BCR-ABL1
transcript levels even after the first year of treatment (Roeder et al,
2006) (Figure 1A). This long-term behaviour cannot be explained
within the model of CML dynamics discussed by Abbott and
Michor (2006). Owing to the contribution of CML cells from the
Figure 1 BCR-ABL1 transcript dynamics for CML under imatinib
treatment: (A) Datapoints represent median and interquartile range of
BCR-ABL1 transcript levels in peripheral blood, determined in two
independent study populations: BCR-ABL1/BCR percentages of 68
individuals with imatinib-treated CML over 1 year, previously published
by Michor et al (2005) (open circles) and BCR-ABL1/ABL1 percentages of
69 individuals with imatinib-treated CML from the German cohort of the
IRIS trial over 5.5 years, previously published by Roeder et al (2006) (filled
circles). (B) Long-term simulation results of BCR-ABL1 levels according to
the model discussed by Abbott and Michor (2006). Parameters are taken
from the original publication of this model (Michor et al, 2005). (C) Long-
term simulation results of BCR-ABL1 levels according to the model
introduced by Roeder et al (2006). Parameters are taken from the given
reference.
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this model inevitably predicts a relapse of BCR-ABL1 transcript
levels after about 1.5 years, even under continuing imatinib
treatment and without the occurrence of resistance mutations
(Figure 1B).
Within the aforementioned publication (Roeder et al, 2006), our
group proposed an alternative explanation of the imatinib effect,
which is consistent with the observed short- and long-term BCR-
ABL1 levels (Figure 1C) as well as with the relapse dynamics after
treatment cessation. In contrast to the model described by Abbott
and Michor, we predict a selective imatinib effect on proliferating
BCR-ABL1-positive cells, including stem cells, whenever they are
activated into cell cycle.
In the light of the clinical long-term data, complemented by our
alternative explanation of the imatinib effect, the statement by
Abbott and Michor – ‘the conclusion that leukaemic stem cells
cannot be depleted by imatinib can safely be drawn’ – cannot be
uphold. In order to correctly describe the long-term dynamics of
BCR-ABL1 transcript levels, certain modifications of the model
are unavoidable. Such modifications could include a (possibly
reduced) imatinib effect on malignant stem cells or a saturating
growth kinetics of the malignant stem cell population.
It should be noted that although our explanation of the imatinib
effect is consistent with the clinically observed long-term
behaviour, it still remains a hypothesis and might not be without
alternative. Particularly in comparison to the hypothesis discussed
by Abbott and Michor (2006), the proposed role of the cell-cycle
status of leukaemic stem cells might point to an important aspect
of the imatinib effect and possibly other tyrosine kinase inhibitors.
It is a particular strength of mathematical models to provide
testable predictions and, therefore, to guide experimental and
clinical research. However, a definite answer whether any
proposed mode of imatinib action is true or not can only be
given by data-based validation.
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